Revaccination after autologous hematopoietic stem cell transplantation is safe and effective in patients with multiple myeloma receiving lenalidomide maintenance Journal Article


Authors: Palazzo, M.; Shah, G. L.; Copelan, O.; Seier, K.; Devlin, S. M.; Maloy, M.; Kenny, S.; Hassoun, H.; Korde, N. S.; Lendvai, N.; Lesokhin, A. M.; Mailankody, S.; Chung, D. J.; Koehne, G.; Landgren, C. O.; Landau, H.; Giralt, S. A.; Perales, M. A.
Article Title: Revaccination after autologous hematopoietic stem cell transplantation is safe and effective in patients with multiple myeloma receiving lenalidomide maintenance
Abstract: Guidelines recommend vaccination starting 12 months after autologous hematopoietic stem cell transplant (aHCT), but there is varying practice for patients on maintenance therapy, with some centers not immunizing at all. Because of decreased vaccine rates among the general population causing loss of herd immunity, we aimed to establish the safety and efficacy of revaccinating multiple myeloma patients on lenalidomide maintenance (LM). Of the 122 patients who were vaccinated after aHCT between 2010 and 2014 at Memorial Sloan Kettering Cancer Center, 91 (75%) were on LM. Vaccine responses were defined by increases between pre- and postvaccination titers. Reponses varied by vaccine type with 76% responding to pertussis, 70% diphtheria, 60% tetanus, 71% Haemophilus influenzae, and 58% pneumococcal. All patients retained minimal levels of polio immunity, but 27% responded with increased titers. Fewer patients received hepatitis A and B, but of those who did, 30% responded to hepatitis A and 40% to hepatitis B. No differences were seen in rates of response for those on LM at time of vaccination compared with those who were not. There were no vaccine-related adverse effects. Reimmunization with inactivated vaccines in patients on LM is therefore both safe and effective, offering this population immunity to vaccine-preventable diseases. © 2017 The American Society for Blood and Marrow Transplantation
Keywords: lenalidomide; multiple myeloma; vaccination; immunization; maintenance; autologous transplant
Journal Title: Biology of Blood and Marrow Transplantation
Volume: 24
Issue: 4
ISSN: 1083-8791
Publisher: Elsevier Inc.  
Date Published: 2018-04-01
Start Page: 871
End Page: 876
Language: English
DOI: 10.1016/j.bbmt.2017.12.795
PROVIDER: scopus
PUBMED: 29288818
PMCID: PMC6673673
DOI/URL:
Notes: Article -- Export Date: 1 May 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Sergio Andres Giralt
    1053 Giralt
  2. Hani Hassoun
    329 Hassoun
  3. Miguel-Angel Perales
    915 Perales
  4. Guenther Koehne
    194 Koehne
  5. Heather Jolie Landau
    419 Landau
  6. Nikoletta Lendvai
    106 Lendvai
  7. Meighan A Palazzo
    15 Palazzo
  8. Sheila A Kenny
    12 Kenny
  9. Alexander Meyer Lesokhin
    363 Lesokhin
  10. David Chung
    240 Chung
  11. Molly Anna Maloy
    269 Maloy
  12. Sean McCarthy Devlin
    601 Devlin
  13. Carl Ola Landgren
    336 Landgren
  14. Neha Sanat Korde
    226 Korde
  15. Gunjan Lalitchandra Shah
    419 Shah
  16. Kenneth Seier
    105 Seier